| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advancing shared decision making for symptom monitoring in people living beyond cancer
|
Heathcote, Lauren C
|
|
2018
|
19 |
10 |
p. e556-e563
|
artikel
|
| 2 |
Alectinib shows CNS efficacy in ALK-positive NSCLC
|
Gourd, Elizabeth
|
|
2018
|
19 |
10 |
p. e520
|
artikel
|
| 3 |
Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma
|
Lambertini, Matteo
|
|
2018
|
19 |
10 |
p. 1264-1266
|
artikel
|
| 4 |
Atezolizumab for metastatic triple-negative breast cancer
|
Stirrups, Robert
|
|
2018
|
19 |
10 |
p. e519
|
artikel
|
| 5 |
A vena caval mass: challenging diagnosis with a rare complication
|
Chan, Albert
|
|
2018
|
19 |
10 |
p. e564
|
artikel
|
| 6 |
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
|
Galimberti, Viviana
|
|
2018
|
19 |
10 |
p. 1385-1393
|
artikel
|
| 7 |
Baseline corticosteroids reduce activity of PD-L1 blockade
|
Gourd, Elizabeth
|
|
2018
|
19 |
10 |
p. e515
|
artikel
|
| 8 |
Camrelizumab for nasopharyngeal carcinoma: a new hope?
|
Kwong, Dora L W
|
|
2018
|
19 |
10 |
p. 1266-1267
|
artikel
|
| 9 |
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
|
Fang, Wenfeng
|
|
2018
|
19 |
10 |
p. 1338-1350
|
artikel
|
| 10 |
Cancer drugs run short in the Gaza Strip
|
Devi, Sharmila
|
|
2018
|
19 |
10 |
p. 1284
|
artikel
|
| 11 |
Cancer trends and disparities in India: data needs for providing equitable cancer care
|
Shastri, Surendra S
|
|
2018
|
19 |
10 |
p. 1260-1261
|
artikel
|
| 12 |
CAR T-cell therapy: perceived need versus actual evidence
|
The Lancet Oncology,
|
|
2018
|
19 |
10 |
p. 1259
|
artikel
|
| 13 |
CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
|
Gourd, Elizabeth
|
|
2018
|
19 |
10 |
p. e516
|
artikel
|
| 14 |
Common analgesics and ovarian cancer prognosis
|
Jie, Jianzheng
|
|
2018
|
19 |
10 |
p. e505
|
artikel
|
| 15 |
Common analgesics and ovarian cancer prognosis
|
Fan, Guohui
|
|
2018
|
19 |
10 |
p. e506
|
artikel
|
| 16 |
Common analgesics and ovarian cancer prognosis – Authors' reply
|
Merritt, Melissa A
|
|
2018
|
19 |
10 |
p. e507
|
artikel
|
| 17 |
Correction to Lancet Oncol 2018; 19: 1315–27
|
|
|
2018
|
19 |
10 |
p. e509
|
artikel
|
| 18 |
Correction to Lancet Oncol 2015; 16: 1473–82
|
|
|
2018
|
19 |
10 |
p. e509
|
artikel
|
| 19 |
Correction to Lancet Oncol 2018; 19: 1155–56
|
|
|
2018
|
19 |
10 |
p. e509
|
artikel
|
| 20 |
Correction to Lancet Oncol 2014; 15: 683–84
|
|
|
2018
|
19 |
10 |
p. 509
|
artikel
|
| 21 |
Correction to Lancet Oncol 2018; 19: e514
|
|
|
2018
|
19 |
10 |
p. e509
|
artikel
|
| 22 |
Correction to Lancet Oncol 2018; 19: e510
|
|
|
2018
|
19 |
10 |
p. e509
|
artikel
|
| 23 |
Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?
|
Ilson, David
|
|
2018
|
19 |
10 |
p. 1285-1286
|
artikel
|
| 24 |
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial
|
Anderson, Richard A
|
|
2018
|
19 |
10 |
p. 1328-1337
|
artikel
|
| 25 |
Does GDPR harm or benefit research participants? An EORTC point of view
|
Negrouk, Anastassia
|
|
2018
|
19 |
10 |
p. 1278-1280
|
artikel
|
| 26 |
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
|
Saad, Fred
|
|
2018
|
19 |
10 |
p. 1404-1416
|
artikel
|
| 27 |
Encorafenib plus binimetinib: an embarrassment of riches
|
Martin-Liberal, Juan
|
|
2018
|
19 |
10 |
p. 1263-1264
|
artikel
|
| 28 |
Follow-up surveillance of Wilms' tumour
|
Fan, Guohui
|
|
2018
|
19 |
10 |
p. e501
|
artikel
|
| 29 |
Follow-up surveillance of Wilms' tumour
|
Zhang, Bin Bin
|
|
2018
|
19 |
10 |
p. e502
|
artikel
|
| 30 |
Follow-up surveillance of Wilm's tumour – Authors' reply
|
Brok, Jesper
|
|
2018
|
19 |
10 |
p. e503
|
artikel
|
| 31 |
GDPR—not just an EU regulation?
|
Williams, Scott
|
|
2018
|
19 |
10 |
p. e508
|
artikel
|
| 32 |
Iniparib for newly diagnosed glioblastoma
|
Das, Manjulika
|
|
2018
|
19 |
10 |
p. e514
|
artikel
|
| 33 |
Instead of feeling blue, go green!
|
Gasparri, Maria Luisa
|
|
2018
|
19 |
10 |
p. 1273-1274
|
artikel
|
| 34 |
Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC
|
Togawa, Kayo
|
|
2018
|
19 |
10 |
p. 1280-1283
|
artikel
|
| 35 |
Maintenance PARP inhibitor therapy: is maintaining quality of life enough?
|
Bouberhan, Sara
|
|
2018
|
19 |
10 |
p. e504
|
artikel
|
| 36 |
Maternal hormonal contraception and childhood leukaemia
|
Pombo-de-Oliveira, Maria S
|
|
2018
|
19 |
10 |
p. 1261-1262
|
artikel
|
| 37 |
Maternal use of hormonal contraception and risk of childhood leukaemia: a nationwide, population-based cohort study
|
Hargreave, Marie
|
|
2018
|
19 |
10 |
p. 1307-1314
|
artikel
|
| 38 |
More evidence for further minimisation of breast-cancer surgery
|
Kuerer, Henry M
|
|
2018
|
19 |
10 |
p. 1272-1273
|
artikel
|
| 39 |
National cancer control plans: a global analysis
|
Romero, Yannick
|
|
2018
|
19 |
10 |
p. e546-e555
|
artikel
|
| 40 |
Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial
|
Frumovitz, Michael
|
|
2018
|
19 |
10 |
p. 1394-1403
|
artikel
|
| 41 |
New ESMO scale ranks mutations as cancer medicine targets
|
Fricker, Janet
|
|
2018
|
19 |
10 |
p. e513
|
artikel
|
| 42 |
No role for induction chemotherapy for head and neck cancers
|
Venkatesan, Priya
|
|
2018
|
19 |
10 |
p. e510
|
artikel
|
| 43 |
Opportunities and priorities for breast surgical research
|
Cutress, Ramsey I
|
|
2018
|
19 |
10 |
p. e521-e533
|
artikel
|
| 44 |
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
|
Dummer, Reinhard
|
|
2018
|
19 |
10 |
p. 1315-1327
|
artikel
|
| 45 |
Parish mortality registers in paleo-oncology
|
Riva, Michele A
|
|
2018
|
19 |
10 |
p. 1288
|
artikel
|
| 46 |
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial
|
Jonasch, Eric
|
|
2018
|
19 |
10 |
p. 1351-1359
|
artikel
|
| 47 |
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
|
Tabernero, Josep
|
|
2018
|
19 |
10 |
p. 1372-1384
|
artikel
|
| 48 |
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer
|
Roviello, Giandomenico
|
|
2018
|
19 |
10 |
p. 1270-1272
|
artikel
|
| 49 |
Preliminary activity of capmatinib with gefitinib in NSCLC
|
Burki, Talha Khan
|
|
2018
|
19 |
10 |
p. e517
|
artikel
|
| 50 |
Protein–metabolite panel for early-stage pancreatic cancer
|
Burki, Talha Khan
|
|
2018
|
19 |
10 |
p. e512
|
artikel
|
| 51 |
Quality of life is not compromised with intensification of androgen therapy in recurrent prostate cancer
|
Seymour, Zachary
|
|
2018
|
19 |
10 |
p. 1275-1276
|
artikel
|
| 52 |
Shortfall of consultant clinical radiologists in the UK
|
Burki, Talha Khan
|
|
2018
|
19 |
10 |
p. e518
|
artikel
|
| 53 |
Talazoparib for BRCA-mutated advanced breast cancer
|
Gunjur, Ashray
|
|
2018
|
19 |
10 |
p. e511
|
artikel
|
| 54 |
The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016
|
|
|
2018
|
19 |
10 |
p. 1289-1306
|
artikel
|
| 55 |
The first prospective trial for von Hippel-Lindau disease: pazopanib
|
Giles, Rachel H
|
|
2018
|
19 |
10 |
p. 1267-1269
|
artikel
|
| 56 |
The impact of Brexit on UK cancer research
|
Lawler, Mark
|
|
2018
|
19 |
10 |
p. 1276-1278
|
artikel
|
| 57 |
TOMAS: revisiting PARP inhibitor combination therapy
|
Nacev, Benjamin A
|
|
2018
|
19 |
10 |
p. 1269-1270
|
artikel
|
| 58 |
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
|
Grignani, Giovanni
|
|
2018
|
19 |
10 |
p. 1360-1371
|
artikel
|
| 59 |
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
|
Lecouvet, Frédéric E
|
|
2018
|
19 |
10 |
p. e534-e545
|
artikel
|
| 60 |
While it is still possible
|
Burki, Talha Khan
|
|
2018
|
19 |
10 |
p. 1287
|
artikel
|
Tijdschrift beschrijving